Lenalid 25mg Natco Capsule Uses, MRP, Price, Cost India.

1. LENALID 25MG Drug profile Lenalid25mg containing active substance known as Lenalidomide which is considered as thalidomide derivative and it is originated from Generic Revlimid. Lenalidomide is a naturally established compound which plays important role in myeloma at first, later it is used for hematological disorders like myelodysplastic syndromes. Lenalidomide is an Immuno modulatory agent which has both anti-angiogenic & anti- cancer activity. Lenalid is available in the strength of 25mg LENALID 25MG Trade name: Lenalid25mg Active ingredient: Lenalidomide Strength: 25mg Mfg: Natco pharma Pack: 30 tablets in a container Classified as: Anti-neoplastic drug Prescribing information of Lenalid 25mg; The most important therapeutic indication of Lenalidomide is given below as follows; In multiple myeloma In myelodysplastic syndrome In mantle cell lymphoma

2. Multiple myeloma: Lenalid25mg(Generic Revlimid) is used in myeloma condition by combining with dexamethasone In myeloma patients with autologous hematopoietic stem cell transplantation, Lenalid25mgis used as a continuation therapy. Myelodysplastic syndrome: Lenalid25mg(Generic Revlimid), is also used in the therapy of patients with transfusion vulnerable anemia expected low or moderate exposure of myelodysplastic syndrome related to deletion 5q cytogenetic aberrant. Mantle cell lymphoma: Lenalid25mg(Generic Revlimid) is used in mantle cell lymphoma as a second line therapy. The patient’s disease conditions are reoccurred or advanced after prior two therapies like Bortezomib. Drawback of use; Lenalid25mgis not suggested in chronic lymphocytic leukemia. Mechanism of Lenalid 25mg; Lenalid25mg(Generic Revlimid), is a thalidomide analogue. The pharmacological activity of Lenalid25mgis; Immuno modulatory Anti-angiogenic activity Anti-neoplastic activity Immuno modulatory effect by; Elevates the counts and activates the effect of T-cells and natural killer cells Elevates the count of natural killer T cells Prohibits the pro-inflammatory cytokines like TNF-alpha & IL-6 monocytes Anti-neoplastic activity by; Prohibiting cell multiplication & activates apoptosis of cancer cells in vitro and causes prohibition of cell growth in vivo, prominently to reduce in tumor strain. Postponing the growth of cancer cells Combined effort of dexamethasone leads to inhibits cell replication and promotes apoptosis in myeloma cells. Anti-angiogenesis; Angiogenesis (cell development) is blocked by reducing the levels of VEGF, TNF-alpha & IL-6. VEGF: Vascular Endothelial Growth Factor Lenalidomide is expel its activity by inhibits the interpretation of cyclo oxygenase 2 (COX 2) in vitro, it may trigger the apoptosis directly by involving in prohibition of bone marrow stromal cell backing by anti-angiogenic and anti-osteoclastogenic activity & by Immuno modulatory effect Absorption

3. After an oral administration of Lenalid 25mg, the absorption occurs very quickly. The peak plasma concentration time occurs between 0.5 to 6 hours after drug intake. Distribution Lenalid25mgis bounds to human plasma protein at relatively 30% Lenalidomide is occurs in semen after administration, at 2 hours & 24 hours after the dose of 25mg Lenalid 25mg. Metabolism The metabolism of Lenalidomide is occurs in limited range, mostly unchanged form of Lenalidomide is a major circulating substance present in the human body. There are two major metabolites like; 5-hydroxy Lenalidomide N-acetyl Lenalidomide Not more than 5% of parent form is present in the circulation. Excretion The primary elimination of Lenalidomide is occurs via renally. Nearly 82% of radioactive dose is eliminated in urine within 24 hours; the two metabolites are excreted in 4.6% & 1.8%. Total excretion occurs within 10 days. The terminal half life period of Lenalidomide in healthy person is 3 hours; whereas in myeloma & MDS or MCL is 3 to 5 hours When to take the tablet Lenalid 25mg Lenalid25mg(Generic Revlimid) should be taken with or without food. Lenalid25mgcapsules should not be opened, broken or chewed. It should be administered with whole water.3 Dosage regimens of Lenalid 25mg The potency of Lenalidomide is not evaluated in pediatric patients with the age of <18 years. In adults; In myelodysplastic syndrome: The recommended dosage is 10mg of Lenalidomide should be taken as a single dose. In renal damaged patients: In CrCl 30 to 60ml/min: 5mg of Lenalidomide should be suggested for once a day. In CrCl <30ml/min: 2.5mg PO as a single dose In CrCl >60ml/min: No dosage adjustment is required Multiple myeloma: The therapy should be followed by combining of Lenalid25mgwith dexamethasone as a single dose. The recommended dose of Lenalid25mgis 25mg should be given as a single dose on day 1 to 21 of repeated 28 day cycles. The dosage of dexamethasone;

4. For first 4 cycles; 40mg of dexamethasone should be recommended on days 1 to 4; 9 to 12; & 17 to 20 of each 28 day cycles. Then followed by 40mg should be given as single dose, days 1 to 4 every 28 days Age >75 years: 20mg of dexamethasone is recommend, on day 1, 8, 15 & 22 of each 28 cycle. Mantle cell lymphoma: The recommended dosage of Lenalid25mgis 25mg should be administered orally as a single dose. CrCl 30 to 60ml/min: 10mg PO single dose CrCl <30ml/min: 15mg should be recommend as a single dose. In ESRD: 5mg should be given Lenalid25mg caused side effects The major adverse effects; Embryo fetal damage Hematological toxicity Venous & arterial thromboembolism Elevation in mortality with CLL Malignancies Liver damage Serious cutaneous reactions Tumor lysis syndrome Tumor flare syndrome Damaged stem cell mobilization Thyroid disorders Increased extinct rate in MCL The most common side effects; Fatigue Asthenia Pyrexia Chest pain Diarrhea Abdominal pain Dyspepsia Back pain Muscle spasms Arthralgia Bone pain Pain in extremity Musculoskeletal pain Neck pain Respiratory infection Pneumonia Influenza Rhinitis

5. Cellulitis Lab abnormalities Anemia Thrombocytopenia Neutropenia Pancytopenia Hypokalemia Hyperglycemia Hypocalcaemia Hypophosphatemia Hyponatremia Other effects; Rash Pruritus Deep vein thrombosis Loss of appetite, weight Insomnia Squamous cell cancer Basal cell cancer Drug - drug interaction of Lenalid 25mg With digoxin: Lenalid25mgis combined used with digoxin causes increasing the plasma concentration of Lenalidomide lead to increase the adverse effects. To avoid this problem, monitor the digoxin plasma concentration periodically during this concomitant. Warfarin: There is no pharmacokinetic changes occurs during this concomitant of Lenalidomide with warfarin, but patients may get alteration in prothrombin time & INR. To avoid this condition, monitor the values frequently during this combinational therapy. Some combination treatment may increase the exposure of thrombosis: Erythropoietic drugs or some other medicines that may elevate the exposure of thrombosis like estrogen containing treatment. This type of concomitant treatment should be used cautiously to reduce the risk factors. Food drug interaction of Lenalid 25mg Food should be avoided during chemotherapy of multiple myeloma; Lenalid25mgcause renal impairment; Food rich in potassium Avocados, bananas, spinach, citrus, tomatoes should be avoided Rich in phosphorus

6. Whole grains, oats, bran cereals, sunflower seeds Food avoid during therapy; Raw meats, sea foods, poultry Unpasteurized dairy Raw sprouts Raw egg Possible contraindications of Lenalid 25mg; Lenalidomide is contraindicated to pregnancy condition, may cause fetal damage Some hyper sensitivity reactions like Stevens Johnsons syndrome, angioedema may occur, due to patients may contraindicate to the components present in Lenalid25mgtablets. Safety measures of Lenalid 25mg; Warning; During Lenalid25mgtherapy, some life threatening conditions may occur like; Embryo fetal damage Hematological toxicity Venous & arterial thromboembolism In tumor flare reaction: This condition may occurs in patients who undergone Lenalidomide therapy, in CLL & lymphoma have chance of getting inflammation on lymph nodes, fever, pain, & rash In liver toxicity: Constant hepatic function test should be done, before and during the therapies. In this condition, treatment should be postponed and continue if required. In tumor lysis syndrome: In this condition, patients must be monitored carefully and precaution should be provide. In allergic conditions: Lenalid25mg treatment should be withheld or discontinue in case of angioedema, rash, bullous rashes. In venous thromboembolism: In MDS, Lenalid25mgis used as a monotherapy, in this condition there is a chance of getting increased exposure of DVT & PE. In hematological risk: Lenalid25mgcauses thrombocytopenia and neutropenia, patients receiving Lenalid25mg for MDS should be completely examine by investigating blood counts weekly for first 8 weeks. In MM patients should be monitored with counting blood cells for every 2 weeks for first 12 weeks and then monthly afterwards. In this condition, dose reduction is applicable. In embryo fetal harm: Lenalidomide is contraindicated to pregnancy conditions.

7. Pregnancy and lactation Pregnancy category: X Lenalid25mgshould not be recommended in pregnancy condition Breast feeding should not be recommended. The initial dose of Lenalidomide is depending upon the creatinine clearance value and for the patients in dialysis. Storage and handling Lenalid25mgtablets should be stores at 20oC to 25oC; excursion between 15oC to 30oC. Keep the container away from heat, moisture & light Missed dose The missed dose of Lenalid25mgshould be avoided, and follow the regular dosing schedule. Over dosage There is no special treatment for over dosage of Lenalidomide; In case of this condition patient must be provided with adjuvant therapy and monitor the signs & symptoms frequently. CONTACTS Phone : +919940472902 USA Toll-Free Call : +18882264402 Email:millionhealthpharmaceuticals@gmail.com WEBSITE: https://millionpharma.us/